MET and non-small cell lung carcinoma: PFKP can bind to AXL and promote AXL phosphorylation at Y799, this activation of AXL further leads to phosphorylation of MET through receptor tyrosine kinase hetero-interaction, and the activation of MET and AXL pathways contribute to NSCLC progression.